AKTX - CIK 0001541157
Akari Therapeutics Plc trades as AKTX. In its fiscal 2023 annual report the company posted revenue of $367.88K, down 39.5% from the prior year and net income of -$17.30M. This page tracks Akari Therapeutics Plc through 710 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| PRE 14A | - | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 |
| RW | - | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-19 |
| NT 10-Q | - | 2026-05-18 |
| IPO registration | S-1 | 2026-05-08 |
| EFFECT | - | 2026-04-15 |
| POS AM | - | 2026-04-10 |
The largest companies sharing Akari Therapeutics Plc's SEC industry classification (pharmaceutical preparations).
Akari Therapeutics Plc reported revenue of $367.88K for fiscal year 2023, a decrease of 39.5% year over year.
In its latest fiscal year Akari Therapeutics Plc reported a net loss of $17.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.